These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 38052042)

  • 1. Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation.
    Frerichs KA; Verkleij CPM; Mateos MV; Martin TG; Rodriguez C; Nooka A; Banerjee A; Chastain K; Perales-Puchalt A; Stephenson T; Uhlar C; Kobos R; van der Holt B; Kruyswijk S; Kuipers MT; Groen K; Vishwamitra D; Skerget S; Cortes-Selva D; Doyle M; Zaaijer HL; Zweegman S; Verona RI; van de Donk NWCJ
    Blood Adv; 2024 Jan; 8(1):194-206. PubMed ID: 38052042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study.
    Usmani SZ; Garfall AL; van de Donk NWCJ; Nahi H; San-Miguel JF; Oriol A; Rosinol L; Chari A; Bhutani M; Karlin L; Benboubker L; Pei L; Verona R; Girgis S; Stephenson T; Elsayed Y; Infante J; Goldberg JD; Banerjee A; Mateos MV; Krishnan A
    Lancet; 2021 Aug; 398(10301):665-674. PubMed ID: 34388396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Newly approved and forthcoming T-cell-redirecting bispecific antibodies for the treatment of relapsed/refractory multiple myeloma.
    Granger K; Gaffney KJ; Davis JA
    J Oncol Pharm Pract; 2023 Apr; 29(3):722-726. PubMed ID: 36775940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 study.
    Nooka AK; Rodriguez C; Mateos MV; Manier S; Chastain K; Banerjee A; Kobos R; Qi K; Verona R; Doyle M; Martin TG; van de Donk NWCJ
    Cancer; 2024 Mar; 130(6):886-900. PubMed ID: 37960969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study.
    Cortes-Selva D; Perova T; Skerget S; Vishwamitra D; Stein S; Boominathan R; Lau O; Calara-Nielsen K; Davis C; Patel J; Banerjee A; Stephenson T; Uhlar C; Kobos R; Goldberg J; Pei L; Trancucci D; Girgis S; Wang Lin SX; Wu LS; Moreau P; Usmani SZ; Bahlis NJ; van de Donk NWCJ; Verona RI
    Blood; 2024 Aug; 144(6):615-628. PubMed ID: 38657201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Redirecting T-cell Activity with Anti-BCMA/Anti-CD3 Bispecific Antibodies in Chronic Lymphocytic Leukemia and Other B-cell Lymphomas.
    Martens AWJ; Rietveld JM; de Boer R; Peters FS; Ngo A; van Mil LWHG; de Heer K; Spaargaren M; Verkleij CPM; van de Donk NWCJ; Adams HC; Eldering E; van Noesel CJM; Verona R; Kater AP
    Cancer Res Commun; 2022 May; 2(5):330-341. PubMed ID: 36875718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Teclistamab in Relapsed or Refractory Multiple Myeloma.
    Moreau P; Garfall AL; van de Donk NWCJ; Nahi H; San-Miguel JF; Oriol A; Nooka AK; Martin T; Rosinol L; Chari A; Karlin L; Benboubker L; Mateos MV; Bahlis N; Popat R; Besemer B; Martínez-López J; Sidana S; Delforge M; Pei L; Trancucci D; Verona R; Girgis S; Lin SXW; Olyslager Y; Jaffe M; Uhlar C; Stephenson T; Van Rampelbergh R; Banerjee A; Goldberg JD; Kobos R; Krishnan A; Usmani SZ
    N Engl J Med; 2022 Aug; 387(6):495-505. PubMed ID: 35661166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed/refractory multiple myeloma.
    Martin TG; Mateos MV; Nooka A; Banerjee A; Kobos R; Pei L; Qi M; Verona R; Doyle M; Smit J; Sun W; Trancucci D; Uhlar C; van de Donk NWCJ; Rodriguez C
    Cancer; 2023 Jul; 129(13):2035-2046. PubMed ID: 36991547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma.
    Pillarisetti K; Powers G; Luistro L; Babich A; Baldwin E; Li Y; Zhang X; Mendonça M; Majewski N; Nanjunda R; Chin D; Packman K; Elsayed Y; Attar R; Gaudet F
    Blood Adv; 2020 Sep; 4(18):4538-4549. PubMed ID: 32956453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Teclistamab: Mechanism of action, clinical, and translational science.
    Guo Y; Quijano Cardé NA; Kang L; Verona R; Banerjee A; Kobos R; Chastain K; Uhlar C; Pillarisetti K; Doyle M; Smit J; Haddish-Berhane N; Ouellet D
    Clin Transl Sci; 2024 Jan; 17(1):e13717. PubMed ID: 38266057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting.
    Zhao J; Ren Q; Liu X; Guo X; Song Y
    J Hematol Oncol; 2023 Aug; 16(1):92. PubMed ID: 37537597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Efficacy of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience.
    Dima D; Davis JA; Ahmed N; Jia X; Sannareddy A; Shaikh H; Shune L; Kaur G; Khouri J; Afrough A; Strouse C; Lochner J; Mahmoudjafari Z; Raza S; Valent J; Anderson LD; Anwer F; Abdallah AO; Hashmi H
    Transplant Cell Ther; 2024 Mar; 30(3):308.e1-308.e13. PubMed ID: 38151105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma.
    Firestone RS; McAvoy D; Shekarkhand T; Serrano E; Hamadeh I; Wang A; Zhu M; Qin WG; Patel D; Tan CR; Hultcrantz M; Mailankody S; Hassoun H; Shah US; Korde N; Maclachlan KH; Landau HJ; Scordo M; Shah GL; Lahoud OB; Giralt S; Murata K; Hosszu KK; Chung DJ; Lesokhin AM; Usmani SZ
    Blood Adv; 2024 Apr; 8(7):1600-1611. PubMed ID: 37878808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population Pharmacokinetics and Exposure-Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1.
    Miao X; Wu LS; Lin SXW; Xu Y; Chen Y; Iwaki Y; Kobos R; Stephenson T; Kemmerer K; Uhlar CM; Banerjee A; Goldberg JD; Trancucci D; Apte A; Verona R; Pei L; Desai R; Hickey K; Su Y; Ouellet D; Samtani MN; Guo Y; Garfall AL; Krishnan A; Usmani SZ; Zhou H; Girgis S
    Target Oncol; 2023 Sep; 18(5):667-684. PubMed ID: 37713090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study.
    Mohan M; Monge J; Shah N; Luan D; Forsberg M; Bhatlapenumarthi V; Balev M; Patwari A; Cheruvalath H; Bhutani D; Thanendrarajan S; Dhakal B; Zangari M; Al-Hadidi S; Cooper D; Lentzsch S; van Rhee F; D'Souza A; Szabo A; Schinke C; Chakraborty R
    Blood Cancer J; 2024 Mar; 14(1):35. PubMed ID: 38443345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies.
    Touzeau C; Krishnan AY; Moreau P; Perrot A; Usmani SZ; Manier S; Cavo M; Martinez Chamorro C; Nooka AK; Martin TG; Karlin L; Leleu X; Bahlis NJ; Besemer B; Pei L; Stein S; Wang Lin SX; Trancucci D; Verona RI; Girgis S; Miao X; Uhlar CM; Chastain K; Garfall AL
    Blood; 2024 Dec; 144(23):2375-2388. PubMed ID: 39172760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elranatamab vs. teclistamab: battle of the BCMA bispecifics in relapsed/refractory multiple myeloma.
    Moore DC; Granger K; Hill H; Karabinos A; Davis JA
    Expert Rev Hematol; 2024 Jun; 17(6):197-200. PubMed ID: 38717927
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma.
    Moreau P; van de Donk NWCJ; Delforge M; Einsele H; De Stefano V; Perrot A; Besemer B; Pawlyn C; Karlin L; Manier S; Leleu X; Weisel K; Ghilotti F; Diels J; Elsada A; Morano R; Strulev V; Pei L; Kobos R; Smit J; Slavcev M; Mateos MV
    Adv Ther; 2023 May; 40(5):2412-2425. PubMed ID: 36961654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies.
    Lancman G; Parsa K; Kotlarz K; Avery L; Lurie A; Lieberman-Cribbin A; Cho HJ; Parekh SS; Richard S; Richter J; Rodriguez C; Rossi A; Sanchez LJ; Thibaud S; Jagannath S; Chari A
    Blood Cancer Discov; 2023 Nov; 4(6):440-451. PubMed ID: 37769148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety, and resistance mechanisms.
    Lee H; Neri P; Bahlis NJ
    Blood; 2024 Mar; 143(13):1211-1217. PubMed ID: 38194680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.